coxsacki
virus
enterovirus
belong
picornavirida
famili
singl
positivestrand
rna
virus
base
lesion
observ
newborn
mice
coxsacki
virus
classifi
two
larg
group
coxsacki
virus
group
six
group
b
pulli
bolanaki
coxsacki
virus
affect
skelet
muscl
coxsacki
b
virus
caus
patholog
chang
sever
tissu
includ
central
nervou
system
pancrea
liver
brown
fat
hyypia
stanway
coxsacki
b
virus
etiolog
agent
wide
spectrum
human
diseas
includ
mild
respiratori
infect
asept
mening
fatal
myocard
outbreak
coxsacki
b
viru
infect
occur
annual
throughout
world
patel
coxsacki
viru
signific
pathogen
acut
chronic
myocard
human
liu
mason
patel
myocard
caus
experi
three
phase
phase
viru
enter
prolifer
myocardium
subsequ
activ
host
immun
system
rare
case
host
immun
activ
continu
unab
despit
elimin
viru
cell
may
target
host
tissu
molecular
mimicri
initi
phase
diseas
stage
cytokin
activ
crossreact
antibodi
may
acceler
cardiac
damag
cumul
effect
may
lead
dilat
cardiomyopathi
diseas
develop
phase
rezkalla
liu
mason
gener
consid
antivir
therapi
would
effect
phase
diseas
process
levi
alejo
liu
mason
potenti
effect
antivir
agent
includ
coxsacki
receptor
blocker
see
till
nucleosid
analogu
kishimoto
heim
immunoglobulin
mcnamara
bozkurt
interferon
ifn
heim
recent
year
synthes
cpg
contain
oligodeoxynucleotid
odn
demonstr
potent
activ
antivir
immun
found
cpg
odn
inhibit
vitro
replic
hepat
b
viru
hiv
type
gurney
schlaepfer
li
local
administr
cpg
odn
inhibit
replic
herp
simplex
viru
type
reduc
incid
sever
genit
herp
mous
model
pyle
ashkar
harandi
addit
cpg
odn
effect
prevent
treat
friend
virusinduc
leukemia
mice
olbrich
cpg
odn
protect
senescenceacceler
mice
lethal
influenza
viru
infect
dong
moreov
previou
studi
show
novel
ctype
cpg
odn
display
strong
antisever
acut
respiratori
syndrom
coronaviru
antivesicular
stomat
viru
activ
vitro
bao
studi
investig
activ
induc
human
peripher
blood
mononuclear
cell
pbmc
type
subtyp
ifn
contribut
activ
nucleaseresist
phosphorothioatemodifi
odn
synthes
sangon
biotech
compani
shanghai
china
cpg
odn
use
studi
krug
marshal
repres
typic
atyp
btype
ctype
humancellstimul
cpg
odn
respect
noncpg
control
except
cg
sequenc
revers
capit
lowercas
letter
repres
phosphorothio
phosphodiest
linkag
respect
odn
dilut
te
buffer
mmol
tri
mmol
edta
ph
use
pyrogenfre
reagent
test
endotoxin
use
limulu
amebocyt
lysat
assay
associ
cape
cod
inc
human
pbmc
isol
buffi
coat
blood
center
jilin
provinc
china
densiti
gradient
centrifug
pharmacia
wash
three
time
iscov
modifi
dulbecco
medium
gibco
viabil
pbmc
determin
trypan
blue
exclus
hela
cell
human
uterin
cervix
cancer
cell
line
atcc
cultur
humidifi
incub
maintain
iscov
modifi
dulbecco
medium
supplement
heatinactiv
fetal
bovin
serum
gibco
antibiot
iu
penicillin
iu
streptomycin
dr
yape
chang
depart
immunolog
jilin
univers
changchun
china
multipli
hela
cell
titrat
cytopath
effect
method
viru
store
aliquot
use
antivir
activ
cultur
supernat
cpg
odntreat
human
pbmc
measur
describ
tokunaga
briefli
supernat
cultur
pbmc
cell
stimul
h
collect
store
aliquot
use
hela
cell
seed
flatbottom
plate
cell
cultur
h
confluenc
cell
incub
supernat
h
challeng
tissuecultur
infecti
dose
h
stain
crystal
violet
cytopath
effect
examin
use
multiwel
microtit
plate
reader
nm
express
od
valu
recombin
human
use
assay
purchas
hansheng
pharmaceut
corp
ltd
zhejiang
china
human
pbmc
cell
treat
h
supernat
harvest
enzymelink
immunosorb
assay
elisa
kit
pierc
use
detect
supernat
accord
manufactur
protocol
supernat
quantit
calcul
base
standard
curv
human
pbmc
cell
treat
h
lyse
total
rna
extract
use
acid
phenolguanidinium
thiocyanatechloroform
method
describ
sambrook
russel
total
rna
ng
revers
transcrib
cdna
reaction
pmol
oligo
dt
primer
u
revers
transcriptas
xl
amv
mmol
dntp
u
rnase
inhibitor
deioniz
reaction
maintain
room
temperatur
min
h
reaction
mixtur
heat
min
denatur
rnacdna
hybrid
quickchil
ice
mixtur
use
pcr
neg
control
reaction
contain
reagent
except
revers
transcriptas
perform
parallel
pcr
perform
u
taq
dna
polymeras
pair
primer
intern
control
primer
consensu
primer
design
amplifi
least
subtyp
includ
sequenc
primer
length
yield
cdna
fragment
show
tabl
primer
synthes
sangon
biotech
compani
shanghai
china
cycl
profil
pcr
follow
denatur
anneal
min
primer
extens
cycl
final
extens
pcr
product
analys
agaros
gel
tae
stain
ethidium
bromid
visual
uv
light
pcr
product
amplifi
consensu
primer
purifi
agaros
gel
freez
thaw
gel
insert
plasmid
vector
takara
dalian
china
dna
ligat
reaction
ligat
mixtur
transform
escherichia
coli
takara
dalian
china
construct
cdna
librari
cell
librari
inocul
onto
agar
sanland
intern
inc
lb
plate
contain
trypton
oxoid
uk
yeast
extract
oxoid
nacl
ampicillin
incub
h
coloni
randomli
pick
plasmid
isol
coloni
identifi
enzym
digest
ecori
hindiii
takara
dalian
china
insert
plasmid
clone
sequenc
sangon
biotech
compani
shanghai
china
conduct
blast
search
sequenc
ncbi
websit
percentag
clone
carri
cdna
repres
variou
subtyp
calcul
data
shown
statist
signific
differ
determin
use
pair
twotail
student
ttest
differ
consid
statist
signific
p
studi
activ
induc
cultur
human
pbmc
one
healthi
donor
cpg
odn
includ
collect
supernat
use
protect
hela
cell
attack
observ
fig
light
microscop
show
supernat
induc
protect
cell
infect
supernat
induc
control
odn
fail
protect
cell
supernat
induc
prototyp
ctype
cpg
odn
prototyp
atyp
cpg
odn
prototyp
btype
cpg
odn
also
effect
protect
cell
krug
marshal
approach
statist
evalu
human
pbmc
eight
healthi
donor
incub
variou
odn
includ
supernat
assay
activ
express
od
valu
bioassay
result
fig
show
compar
medium
control
could
significantli
stimul
pbmc
produc
substanc
protect
hela
cell
infect
respect
wherea
fail
induc
signific
protect
togeth
data
indic
atyp
ctype
cpg
odn
effect
induc
reaction
human
pbmc
next
investig
dose
effect
kinet
induc
activ
doseeffect
assay
human
pbmc
stimul
variou
amount
supernat
collect
assay
activ
result
fig
show
induc
evid
protect
hela
cell
protect
increasingli
evid
dose
increas
reach
peak
activ
induc
display
similar
profil
contrast
activ
induc
inferior
induc
kinet
assay
human
pbmc
cultur
supernat
collect
variou
time
point
test
result
fig
show
appar
activ
induc
h
peak
activ
occur
h
maintain
h
comparison
supernat
display
activ
conduct
analysi
test
activ
induc
activ
recombin
human
parallel
supernat
dilut
cultur
human
pbmc
variou
concentr
test
activ
shown
fig
profil
anticvb
activ
induc
similar
plateau
decreas
gradual
base
intersect
two
curv
could
deduc
supernat
show
equal
activ
iu
investig
mechan
involv
activ
induc
assess
express
variou
type
ifn
subtyp
ifn
induc
basi
result
shown
fig
isol
total
mrna
human
pbmc
incub
h
time
point
activ
obvious
induc
use
revers
transcriptas
rt
pcr
mrna
total
mrna
analys
mrna
use
intern
control
result
show
human
pbmc
express
mrna
fig
higher
level
mrna
induc
result
impli
activ
induc
may
correl
express
increas
evid
major
factor
confer
antivir
activ
human
bodi
therefor
evalu
produc
human
pbmc
number
healthi
donor
pbmc
six
donor
treat
h
supernat
harvest
detect
elisa
kit
result
show
could
induc
six
donor
pbmc
produc
level
rang
pg
control
odn
induc
fig
data
confirm
activ
human
pbmc
secret
high
level
clarifi
subtyp
induc
tri
analys
mrna
express
profil
subtyp
amino
acid
homolog
among
subtyp
difficult
distinguish
antibodybas
method
elisa
furthermor
absenc
intron
gene
subtyp
similar
size
gene
subtyp
make
imposs
discrimin
subtyp
rtpcr
conduct
analysi
total
mrna
isol
pbmc
healthi
donor
whose
pbmc
treat
produc
pg
total
cdna
amplifi
consensu
primer
rtpcr
use
construct
cdna
librari
insert
fifti
clone
librari
randomli
sequenc
numer
found
clone
carri
cdna
compris
clone
librari
clone
posit
detect
fig
data
demonstr
stimul
human
pbmc
express
least
subtyp
mrna
suggest
potenti
stimul
product
subtyp
result
studi
demonstr
vitro
incub
human
pbmc
induc
activ
activ
parallel
express
subtyp
data
suggest
may
consider
therapeut
potenti
treatment
infect
induc
mix
natur
ifn
signific
pathogen
acut
chronic
myocard
human
liu
mason
patel
acut
myocard
character
rapid
develop
lifethreaten
congest
heart
failur
arrhythmia
later
stage
diseas
excess
immun
respons
might
aggrav
myocyt
destruct
experi
mice
shown
antivir
treatment
consist
ifn
immunoglobulin
nucleosid
analogu
earli
stage
diseas
could
limit
develop
levi
alejo
liu
mason
find
induc
signific
activ
human
pbmc
h
administr
impli
could
use
altern
medic
earli
treatment
infect
vitro
induct
activ
human
pbmc
probabl
result
ifn
product
upon
invas
virus
cell
human
bodi
produc
variou
type
ifn
includ
limit
viru
infect
human
immun
system
plasmacytoid
dendrit
cell
express
tolllik
receptor
respons
target
cell
cpg
odn
respect
antivir
reaction
krug
challeng
virus
plasmacytoid
dendrit
cell
capabl
secret
larg
amount
level
thousand
time
typic
produc
cell
siegal
result
present
impli
signific
control
infect
might
achiev
vivo
inject
induc
type
ifn
ifn
report
inhibit
replic
virus
activ
natur
killer
cell
pestka
kill
virusinfect
cell
facilit
gener
cytotox
lymphocyt
conduct
power
kill
virusinfect
cell
human
least
subtyp
maeda
pestka
pestka
gener
believ
transcript
variou
speci
modul
multipl
signal
pathway
depend
viru
type
cell
infect
found
distinct
viru
may
induc
characterist
profil
ifn
product
exampl
newcastl
diseas
viru
preferenti
induc
subtyp
infect
cell
barn
hepat
c
viru
induc
increas
pbmc
sendai
viru
caus
human
peripher
blood
leucocyt
express
least
nine
speci
includ
nyman
hand
differ
subtyp
seem
exhibit
differ
profil
antivir
activ
cajeanferoldi
exampl
antivesicular
stomat
viru
effect
vitro
due
exist
schanen
recombin
human
could
inhibit
replic
hepat
c
viru
among
least
effect
koyama
result
induc
subtyp
human
gene
portfolio
suggest
activ
induc
correl
product
mix
balanc
ratio
addit
type
ifn
may
also
contribut
activ
induc
induc
togeth
induc
activ
natur
killer
cell
kill
cell
earli
stage
infect
ongo
immun
respons
induc
promot
virusinfect
cell
express
major
histocompat
complex
protein
facilit
recognit
cell
surfacebound
viral
antigen
cytolysi
virusinfect
cell
cytotox
lymphocyt
properti
induc
natur
mix
type
ifn
subtyp
may
make
promis
agent
develop
treatment
infect
virusassoci
diseas
comparison
wide
use
recombin
ifn
may
sever
advantag
treatment
viru
infect
first
induc
mix
ifn
wherea
recombin
ifn
current
use
usual
singl
type
ifn
instanc
recombin
use
treat
hepat
c
hepat
b
genit
wart
kaposi
sarcoma
hairi
cell
leukemia
chronic
myelogen
leukemia
malign
melanoma
advanc
hepatocellular
carcinoma
diseas
samuel
braiteh
kurokohchi
sarin
ward
kugelma
use
treatment
relaps
form
multipl
sclerosi
banwel
derwensku
lublin
obvious
synergist
action
mix
ifn
effect
singl
type
ifn
second
advantag
phosphorothio
backbon
resist
endogen
nucleas
therefor
longer
halflif
vitro
vivo
sand
yu
comparison
human
bodi
halflif
regular
recombin
h
longterm
recombin
carri
polyethylen
glycol
h
glue
third
advantag
induc
endogen
ifn
immunogen
human
bodi
repeat
use
recombin
ifn
report
induc
ifnneutr
antibodi
hinder
continu
therapi
oberg
alm
lok
noteworthi
natur
occur
ifn
prove
higher
antivir
activ
recombin
counterpart
vitro
heim
dahl
